Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: Campral
Published 2025-12-23 · Last reviewed 2025-12-30 · 4 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Acamprosate (brand Campral; generics) is indicated to support maintenance of abstinence in alcohol use disorder (AUD) in people who are abstinent at treatment initiation (label).
It is not an acute alcohol withdrawal medication; withdrawal management is typically handled separately, then relapse-prevention options (such as acamprosate or naltrexone) are considered as follow-up care continues (guideline/clinical).
A practical differentiator is that acamprosate has minimal hepatic metabolism and is primarily renally eliminated. This can be helpful in people with liver disease but requires renal assessment and dose-adjustment constraints (label).
Evidence syntheses and guidelines describe modest but clinically meaningful benefits on abstinence outcomes when paired with structured support (review/guideline).
The compare view, acamprosate evidence feed, and acamprosate print page support shared decision-making when alcohol use disorder treatment is discussed alongside mood symptoms and relapse-risk planning.
Often selected when the treatment goal is abstinence and when liver disease or opioid co-use makes alternatives less suitable. Practical limitations include multiple daily dosing and GI tolerability.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
The exact mechanism is not fully established. Label and review sources describe acamprosate as modulating glutamatergic and GABAergic systems, supporting neurochemical stabilization during abstinence (label/review).
It is best conceptualized as a relapse-prevention medication used after detoxification rather than as a medication that treats acute withdrawal symptoms (guideline/clinical).
Medication choice is commonly revisited after early stabilization to ensure the regimen matches the person’s goals (abstinence vs reduction), medical comorbidities, and ability to adhere to the dosing schedule.